// App-Quantinova.ai

TCT-468 : Acute Thrombogenicity and Inflammation in Response to a Durable Fluoropolymer Everolimus-Eluting Stent Relative to a Contemporary Sirolimus-Eluting Stent with an Abluminal Biodegradable Polymer Coating

Researchers

Presenter

  • Sho Torii

Principal Investigators

  • Qi Cheng

  • Frank Kolodgie

  • Renu Virmani

  • Eduardo Acampado

  • Kazuyuki Yahagi

  • Hiroyoshi Mori

  • Maria Romero

  • Laura Perkins

  • Syed Hossainy

  • Stephen Pacetti

  • Aloke Finn

Medical Centers

  • CVPath institute, North Bethesda, Maryland, United States

  • CVPath Institute Inc.

  • CVPath Institute Inc.

Locations

  • United States

Companies

  • Abbott

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Cluster of Differentiation 14

  • Integrin subunit beta 3

Drug/Treatment

  • sirolimus

  • Everolimus

  • Lercanidipine hydrochloride

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved